Literature DB >> 29427491

Managing hepatitis C in patients with the complications of cirrhosis.

Marcus M Mücke1, Victoria T Mücke1, Christian M Lange1, Stefan Zeuzem1.   

Abstract

Direct acting antivirals (DAA) have revolutionized the treatment of hepatitis C virus (HCV). Sustained virological response rates of nearly 100% have become common in the general population. However, physicians face the growing problem of managing HCV in patients with the complications of cirrhosis, eg hepatic decompensation or hepatocellular carcinoma (HCC). Safety and efficacy remain a clinical challenge in these difficult-to-treat patients. This review focuses on the current state of knowledge and treatment regimens in patients with decompensated cirrhosis as well as the potential risk of the development of HCC following DAA therapy.
© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  decompensated cirrhosis; difficult-to-treat patients; hepatitis C virus; hepatocellular carcinoma

Mesh：

Substances：

Year:  2018        PMID： 29427491     DOI： 10.1111/liv.13636

Source DB:  PubMed          Journal:  Liver Int        ISSN： 1478-3223            Impact factor:   5.828


  5 in total

1.  The impact of direct-acting antiviral agents on liver and kidney transplant costs and outcomes.

Authors:  D A Axelrod; M A Schnitzler; T Alhamad; F Gordon; R D Bloom; G P Hess; H Xiao; M Nazzal; D L Segev; V R Dharnidharka; A S Naik; N N Lam; R Ouseph; B L Kasiske; C M Durand; K L Lentine
Journal:  Am J Transplant       Date:  2018-05-29       Impact factor: 8.086

2.  Pre-Senescence Induction in Hepatoma Cells Favors Hepatitis C Virus Replication and Can Be Used in Exploring Antiviral Potential of Histone Deacetylase Inhibitors.

Authors:  Alsu Z Malikova; Anastasia S Shcherbakova; Konstantin A Konduktorov; Anastasia S Zemskaya; Alexandra A Dalina; Vladimir I Popenko; Olga G Leonova; Alexei V Morozov; Nikolay N Kurochkin; Olga A Smirnova; Sergey N Kochetkov; Maxim V Kozlov
Journal:  Int J Mol Sci       Date:  2021-04-27       Impact factor: 5.923

3.  Utility of the new cobas HCV test for viral load monitoring during direct-acting antiviral therapy.

Authors:  Marcus M Mücke; Benjamin Maasoumy; Julia Dietz; Victoria T Mücke; Christian O Simon; Jesse A Canchola; Marcus Cornberg; Ed G Marins; Michael P Manns; Stefan Zeuzem; Heiner Wedemeyer; Christoph Sarrazin; Johannes Vermehren
Journal:  PLoS One       Date:  2019-11-18       Impact factor: 3.240

4.  Direct-acting antivirals for chronic hepatitis C treatment: The experience of two tertiary university centers in Brazil.

Authors:  Mariana Sandoval Lourenço; Patricia Momoyo Y Zitelli; Marlone Cunha-Silva; Arthur Ivan N Oliveira; Cláudia P Oliveira; Tiago Sevá-Pereira; Flair José Carrilho; Mario G Pessoa; Daniel F Mazo
Journal:  World J Hepatol       Date:  2022-01-27

5.  Relation of Reduction of Antibodies against Hepatitis B Virus to Hepatocellular Carcinoma Recurrence in the Patients with Resolved Hepatitis B Virus Infection Following Direct-acting Antiviral Therapy for Hepatitis C Virus Infection.

Authors:  Kouji Joko; Toshie Mashiba; Hironori Ochi; Ryo Yano; Kaori Sato; Yusuke Okujima; Michiko Aono; Nobuaki Azemoto; Shunji Takechi; Tomoyuki Yokota; Ryosuke Jinoka; Yasunori Moriyama; Masataka Nishiyama
Journal:  Euroasian J Hepatogastroenterol       Date:  2019 Jul-Dec
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.